Evidence map›Paper›PMID 38300923›Full record

ArticlePLOS global public health2024

Impact of post-COVID-19 lung damage on pulmonary function, exercise tolerance and quality of life in Indian subjects.

Devasahayam Jesudas Christopher, Barney T J Isaac, Flavita Benna John, Deepa Shankar, Prasanna Samuel, Richa Gupta, Balamugesh Thangakunam

Open access · goldAbstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Incentive Spirometer in COVID-19: A Systematic Review.Journal of clinical medicine · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Pulmonary manifestations of long COVID in Johannesburg, South Africa.Southern African journal of infectious diseases · 2025
    Article
  8. Article
  9. Evaluating myelophil, a 30% ethanol extract ofFrontiers in pharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Devasahayam Jesudas ChristopherDepartment of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India.ORCID https://orcid.org/0000-0002-9405-8494
Barney T J IsaacDepartment of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
Flavita Benna JohnDepartment of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
Deepa ShankarDepartment of Pulmonary Medicine, Respiratory Therapist & Research Co-ordinator, Christian Medical College, Vellore, Tamil Nadu, India.ORCID https://orcid.org/0009-0006-0492-4392
Prasanna SamuelDepartment of G.I. Sciences & Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.
Richa GuptaProfessor and Head of Respiratory Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
Balamugesh ThangakunamDepartment of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India.ORCID https://orcid.org/0000-0001-6799-065X
Christian Medical College, Vellore · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After recovery from COVID-19, there is data to suggest potential long-term pulmonary sequelae and associated impairment of functional capacity. This cross-sectional study was designed to assess the impact on respiratory function in a cohort of Indian subjects. Subjects who had recovered from COVID-19 were recruited. Clinical symptoms, pulmonary function test results, 6-minute walk test (6MWT) results, St George's Respiratory questionnaire (SGRQ) and chest radiographs were obtained. Information on the COVID-19 illness during hospitalization, baseline laboratory biomarkers and the disease severity categories as outlined by WHO (asymptomatic, mild, moderate, severe and critical), were retrieved from the hospital records. The 'COVID pneumonia'(WHO category moderate, severe & critical) group was compared with the 'Mild COVID' (WHO category mild) group and likewise, the WHO category moderate and the WHO category severe/critical groups were compared. In 207 subjects, whose mean age was 48.7 years were assessed after an average of 63 days from onset of symptom, 35% had TLC< 80% (restrictive defect), 8.3% had FEV1/FVC<70% (obstructive defect) and 44.4% had diminished DLCO<80% (diffusing capacity). The 'COVID-19 pneumonia' group when compared to the 'mild COVID-19' group, had lower FVC% (77.85 VS 88.18; P = 0.001), TLC% (79.48 VS 87.91; P = 0.0002), DLCO% (75.30 VS 89.20; P<0.0001) and DLCO/VA% (105.6 VS 111.8; P = 0.032), decreased minimum oxygen saturation (94.89 VS 97.73; P<0.0001) and more subjects had a drop in saturation of ≥ 4% (21.69% VS 4.84%; P = 0.001) during the 6MWT, and a greater mean total SGRQ score (29.2 VS 11.0; P<0.0001). To our knowledge, this is the first such report on Indian subjects. We have shown that post-COVID-19 lung damage leads to significant impairment of lung function, quality of life and effort tolerance.

Identifiers

PMID38300923
PMCPMC10833535
OpenAlexW4391428787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.